BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37356828)

  • 1. Difficult-to-treat resistant gram-negative blood stream infections - the beginning of a superbug era - a prospective observational study.
    P N; Kumar D; Meena DS; R NT; Bohra GK; Tak V; Sharma A; Midha NK; Garg MK
    Indian J Med Microbiol; 2023; 44():100364. PubMed ID: 37356828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Difficult-to-Treat Resistance in Gram-negative Bacteremia on Mortality: Retrospective Analysis of Nationwide Surveillance Data.
    Huh K; Chung DR; Ha YE; Ko JH; Kim SH; Kim MJ; Huh HJ; Lee NY; Cho SY; Kang CI; Peck KR; Song JH;
    Clin Infect Dis; 2020 Dec; 71(9):e487-e496. PubMed ID: 31994704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents.
    Kadri SS; Adjemian J; Lai YL; Spaulding AB; Ricotta E; Prevots DR; Palmore TN; Rhee C; Klompas M; Dekker JP; Powers JH; Suffredini AF; Hooper DC; Fridkin S; Danner RL;
    Clin Infect Dis; 2018 Nov; 67(12):1803-1814. PubMed ID: 30052813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for sepsis by carbapenem resistant Gram-negative bacilli in adult critical patients in Rio de Janeiro: a case-case-control design in a prospective cohort study.
    Lima EM; Cid PA; Beck DS; Pinheiro LHZ; Tonhá JPS; Alves MZO; Lourenço ND; Santos RQ; Asensi MD; Marques JA; Bandeira CS; Rodrigues CAS; Gomes Junior SCS; Gomes MZR;
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):132. PubMed ID: 32795380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies.
    Savoldi A; Carrara E; Piddock LJV; Franceschi F; Ellis S; Chiamenti M; Bragantini D; Righi E; Tacconelli E
    BMC Infect Dis; 2021 Jun; 21(1):545. PubMed ID: 34107899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
    Ardebili A; Izanloo A; Rastegar M
    Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization and risk factors for carbapenem-resistant Gram-negative bacilli colonization in children: emergence of NDM-producing Acinetobacter baumannii in a newborn intensive care unit in Turkey.
    Karaaslan A; Soysal A; Altinkanat Gelmez G; Kepenekli Kadayifci E; Söyletir G; Bakir M
    J Hosp Infect; 2016 Jan; 92(1):67-72. PubMed ID: 26601601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections.
    Giannella M; Bussini L; Pascale R; Bartoletti M; Malagrinò M; Pancaldi L; Toschi A; Ferraro G; Marconi L; Ambretti S; Lewis R; Viale P
    Open Forum Infect Dis; 2019 Dec; 6(12):ofz505. PubMed ID: 31858018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of carbapenem-resistant Gram-negative infections globally.
    Brink AJ
    Curr Opin Infect Dis; 2019 Dec; 32(6):609-616. PubMed ID: 31567571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbapenem-resistant gram-negative bacterial infection in intensive care unit patients: Antibiotic resistance analysis and predictive model development.
    Liao Q; Feng Z; Lin H; Zhou Y; Lin J; Zhuo H; Chen X
    Front Cell Infect Microbiol; 2023; 13():1109418. PubMed ID: 36794004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and Outcome of Carbapenem-Resistant Gram-Negative Bacilli Blood-Stream Infections in a Tertiary Care Hospital.
    Shah PG; Shah SR
    J Assoc Physicians India; 2015 Jul; 63(7):14-8. PubMed ID: 26731822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study.
    Strich JR; Warner S; Lai YL; Demirkale CY; Powers JH; Danner RL; Kadri SS
    Lancet Infect Dis; 2020 Oct; 20(10):1172-1181. PubMed ID: 32505231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDR/XDR/PDR or DTR? Which definition best fits the resistance profile of Pseudomonas aeruginosa?
    Cosentino F; Viale P; Giannella M
    Curr Opin Infect Dis; 2023 Dec; 36(6):564-571. PubMed ID: 37930070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe infections caused by difficult-to-treat Gram-negative bacteria.
    Dettori S; Portunato F; Vena A; Giacobbe DR; Bassetti M
    Curr Opin Crit Care; 2023 Oct; 29(5):438-445. PubMed ID: 37641512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of blood stream infections in pediatric patients at a Tertiary Care Cancer Centre.
    Thacker N; Pereira N; Banavali SD; Narula G; Vora T; Chinnaswamy G; Prasad M; Kelkar R; Biswas S; Arora B
    Indian J Cancer; 2014; 51(4):438-41. PubMed ID: 26842152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New evidence for managing Gram-negative bloodstream infections.
    Nutman A; Tellapragada C; Giske CG; Yahav D
    Curr Opin Infect Dis; 2021 Dec; 34(6):599-610. PubMed ID: 34636349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of gram-negative bacteria with difficult-to-treat resistance: definition, prevalence, and treatment options.
    Zhuo J; Liang B; Zhang H; Chi Y; Cai Y
    Expert Rev Anti Infect Ther; 2023; 21(11):1203-1212. PubMed ID: 37811630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Can a difficult-to-treat resistance approach improve cooperation between microbiologists and clinicians?].
    Kroneislová G; Závora J; Adámková V
    Klin Mikrobiol Infekc Lek; 2022 Jun; 28(2):52-58. PubMed ID: 36546471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
    Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for tracheobronchial acquisition of resistant Gram-negative bacterial pathogens in mechanically ventilated ICU patients.
    Papakonstantinou I; Angelopoulos E; Baraboutis I; Perivolioti E; Parisi M; Psaroudaki Z; Kampisiouli E; Argyropoulou A; Nanas S; Routsi C
    J Chemother; 2015 Oct; 27(5):283-9. PubMed ID: 24981117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.